Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases... Show more
PCVX broke above its upper Bollinger Band on April 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In of the 38 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCVX's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PCVX just turned positive on April 17, 2025. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 226 cases where PCVX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.256) is normal, around the industry mean (14.767). P/E Ratio (0.000) is within average values for comparable stocks, (65.482). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.018). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.233).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PCVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
WEBL | 23.59 | 2.48 | +11.75% |
Direxion Daily Dow Jones Int Bl 3X ETF | |||
WCLD | 36.17 | 1.51 | +4.36% |
WisdomTree Cloud Computing ETF | |||
BHFAL | 20.01 | 0.13 | +0.65% |
Brighthouse Financial | |||
DIVI | 34.41 | 0.21 | +0.61% |
Franklin Intl Core Div Tlt Idx ETF | |||
DRIP | 10.46 | -0.84 | -7.43% |
Direxion Dly S&P Oil&Gs Ex&Prd Br 2X ETF |
A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with LOGC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then LOGC could also see price increases.
Ticker / NAME | Correlation To PCVX | 1D Price Change % | ||
---|---|---|---|---|
PCVX | 100% | +1.38% | ||
LOGC - PCVX | 45% Loosely correlated | +2.59% | ||
ORKA - PCVX | 44% Loosely correlated | +2.20% | ||
RCKT - PCVX | 44% Loosely correlated | +0.14% | ||
DYN - PCVX | 41% Loosely correlated | +10.08% | ||
BHVN - PCVX | 38% Loosely correlated | +1.58% | ||
More |